The latest news from debra of America, from organizational happenings and inspiring stories to expert insights and research updates.

2024 DCC Planning Committee

Meet the Faces Behind the DCC Planning Committee

April 22, 2024
The countdown has begun for the 2024 debra Care Conference (DCC) on July 28-31 in vibrant Atlanta, GA! This extraordinary gathering brings together individuals and families impacted by Epidermolysis Bullosa (EB), alongside leading experts in the field, for four days of education, connection, and…
SuzanneHead-FlyingPigMarathon

TEAM DEBRA Spotlight: Suzanne Head in the Flying Pig Marathon

April 08, 2024
Joining our endurance team, TEAM DEBRA, in the Flying Pig Marathon in Cincinnati, OH on May 4-5, 2024 is the amazing Suzanne Head. Suzanne will be taking on the Half Marathon in memory of her daughter, Harlee Bass, who lived with Recessive Dystrophic Epidermolysis Bullosa (RDEB). “TEAM DEBRA has…
Wound Care Products Epidermolysis Bullosa

Choosing Wound Care Supplies for your Unique Needs

March 06, 2024
As debra of America's EB Nurse, I have the privilege of speaking to many people with questions about wound care. Wound care is a critical aspect of managing Epidermolysis Bullosa (EB) effectively. EB is characterized by fragile skin prone to wounds and blisters. Wound care for someone with EB…
Nick Meisinger Los Angeles Marathon TEAM DEBRA

TEAM DEBRA Spotlight: Nick Meisinger in the Los Angeles Marathon

February 06, 2024
Joining debra of America’s endurance team, TEAM DEBRA, in the Los Angeles Marathon this March is Nick Meisinger! Nick prepares to take on the challenging 26.2 miles as a heartfelt tribute to his cousin's late child, Theo, who lived with Severe Junctional Epidermolysis Bullosa.   “Theo was born…
Epidermolysis Bullosa Wound Care Distribution Program

Bridging Gaps and Moving Forward: Our Wound Care Distribution Program Journey

January 31, 2024
In the heart of debra of America’s mission to support those battling Epidermolysis Bullosa (EB), is our Wound Care Distribution Program. With the recent relocation of our headquarters from New York to Colorado, we're not just changing our address; we're enhancing our capacity to serve and support…
Boulder Colorado debra of America New Office

We've Moved our HQ to Boulder, CO!

January 26, 2024
Exciting news —After four decades in the bustling Big Apple, we’ve moved our headquarters to beautiful Boulder, Colorado! This new location will allow our dedicated team to better serve and support our Epidermolysis Bullosa (EB) Community. Our office is located at 1023 Walnut Street, Suite 100,…
Chiesi Epidermolysis Bullosa

The U.S. FDA Approves FILSUVEZ topical gel for JEB and DEB

December 19, 2023
debra of America is thrilled to announce a groundbreaking milestone for the Epidermolysis Bullosa (EB) Community: The U.S. Food and Drug Administration (FDA) has granted approval for FILSUVEZ® (birch triterpenes) topical gel for the treatment of partial thickness wounds in patients 6 months and…
Scott Kerns Abeona Therapeutics #GivingTuesday

#GivingTuesday Spotlight: Scott Kerns

November 28, 2023
Today marks #GivingTuesday, a global generosity movement unleashing the power of people and organizations to transform their communities and the world. As we reflect on the incredible individuals who have made a lasting impact on debra of America’s mission, we are thrilled to shine a spotlight on…
Willistine Lenon Aegle Therapeutics #GivingTuesday

#GivingTuesday Spotlight: Willistine Lenon

November 27, 2023
As we approach #GivingTuesday, a day dedicated to the spirit of generosity and giving back, we are delighted to shine a spotlight on a special supporter and advocate —Willistine Lenon, Vice President of Clinical Operations at Aegle Therapeutics, a biotechnology company that is developing an…
Abeona Therapeutics Epidermolysis Bullosa

The U.S. FDA Accepts Pz-cel for Priority Review and Sets PDUFA Date

November 27, 2023
Big news from Abeona Therapeutics —The U.S. Food and Drug Administration has granted Priority Review for the Biologics License Application for Pz-cel (prademagene zamikeracel), which means that they are fast-tracking their decision on whether to approve it. The FDA is aiming to make that decision…